Private Banking|Professional Solutions|Investment Management|Investment Banking|About us
  • Solutions
  • Sectors
  • Careers
Jul 2019
Joint Bookrunner
€ 116 million
Secondary placing of Fagron shares


Joint Bookrunner

Kempen acted as Joint Bookrunner in the secondary placing of Fagron shares

Transaction highlights

  • Placing of 7,184,391 existing ordinary shares representing c. 10% of Fagron’s outstanding share capital by WPEF VI Holdco III BE B.V., jointly owned by Waterland Private Equity Fund VI C.V. and Baltisse NV
  • Offer price of €16.2 per share, which is a 8.4% discount to the last closing price on 2 July 2019 
  • Gross proceeds amount to c. € 116.4 million 
  • The selling shareholder still holds 20.2% of Fagron’s outstanding share capital post-transaction
  • Kempen has been actively marketing Fagron via roadshows, investor calls, and our conference
  • This successful transaction marks Kempen’s seventh Life Sciences ECM transaction in 2019 


Company description

Fagron is a Belgium based pharmaceuticals company focused on delivering personalised medicine to hospitals, clinics, pharmacies and patients in Europe, North America and Latin America. Fagron covers the entire value chain of personalised medicine including essentials & brands, compounding services, and premium pharmaceuticals.

Fully focused on your future

Private Banking
  • Offices
  • Entrepreneurs
  • Healthcare
  • Executives
  • Business professionals
  • Wealth management
  • Conditions
  • Private Banking - Belgium
  • Private Banking - Switzerland

Professional Solutions
Investment Management
Investment Banking

© Van Lanschot Kempen NV 2024About usSecurity and fraud awarenessPrivacy & cookiesDisclaimer